1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

CombiGene: Preclinical experts in gene therapy

[ingress]

• Focus on out-licensing CG01 again

• Promising development in the COZY programme

• We initiate coverage with a fair value of SEK 12.19 per share

The prospects for gene therapies have raised the hopes and expectations of patients, healthcare professionals and investors in the life sciences industry. The first therapies have been approved, and more are on the way. Gene therapies are expected to take off in the 2020s as global pharmaceutical companies compete to position themselves in a field with great medical and commercial potential. Swedish gene therapy specialist CombiGene focuses on discovering promising projects, developing them into the clinical phase and out-licensing them after achieving preclinical proof of concept.

Västra Hamnen initiates research coverage of CombiGene with a fair value of SEK 12.19 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)

Datum 2024-06-20, kl 09:30
Källa MFN
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.